Telomir Pharmaceuticals Management
Management criteria checks 0/4
Telomir Pharmaceuticals' CEO is Erez Aminov, appointed in Aug 2024, has a tenure of less than a year. total yearly compensation is $7.79M, comprised of 1.4% salary and 98.6% bonuses, including company stock and options. directly owns 0.099% of the company’s shares, worth $65.12K. The average tenure of the management team and the board of directors is 0.8 years and 1.2 years respectively.
Key information
Erez Aminov
Chief executive officer
US$7.8m
Total compensation
| CEO salary percentage | 1.36% |
| CEO tenure | less than a year |
| CEO ownership | 0.1% |
| Management average tenure | less than a year |
| Board average tenure | 1.2yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$12m |
| Dec 31 2024 | US$8m | US$106k | -US$17m |
Compensation vs Market: Erez's total compensation ($USD7.79M) is above average for companies of similar size in the US market ($USD645.80K).
Compensation vs Earnings: Insufficient data to compare Erez's compensation with company performance.
CEO
Erez Aminov (45 yo)
Mr. Erez Aminov is Chairman of the Board and Chief Executive Officer at Telomir Pharmaceuticals, Inc. since August 08, 2024. He is Chief Executive Officer of MIRA Pharmaceuticals, Inc. from April 28, 2023...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | less than a year | US$7.79m | 0.099% $ 65.1k | |
| CFO, Treasurer & Secretary | less than a year | US$929.83k | 0.082% $ 53.7k | |
| Chief Scientific Advisor | less than a year | no data | no data |
Experienced Management: TELO's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | less than a year | US$7.79m | 0.099% $ 65.1k | |
| Independent Director | 2.5yrs | no data | 1.64% $ 1.1m | |
| Independent Director | 1.2yrs | no data | no data | |
| Independent Director | 1.2yrs | no data | no data | |
| Independent Director | less than a year | no data | no data |
Experienced Board: TELO's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 05:39 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Telomir Pharmaceuticals, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bradley Sorensen | Zacks Small-Cap Research |